The article discusses the lessons learned by U.S. medical geneticist James M. Wilson who ran the clinical gene therapy trial that led to the death of Jesse Gelsinger from multiorgan failure. Topics include an overview of how Gelsinger's death changed gene therapy, the career of Wilson, including his publication of "Molecular Genetics and Metabolism" documenting his experience, and an overview of the trial he conducted investigating therapy for ornithine transcarbamylase (OTC) deficiency.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados